<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Billiontoone, Inc. Class A Common Stock — News on 6ix</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock</link>
<description>Latest news and press releases for Billiontoone, Inc. Class A Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 02 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/billiontoone-inc-class-a-common-stock" rel="self" type="application/rss+xml" />
<item>
<title>BillionToOne Appoints Dr. Allen Chen as Vice President of Medical Affairs and Clinical Development, Oncology</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-appoints-dr-allen-chen-as-vice-president-of-medical-affairs-and-clinical-development-oncology-6</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-appoints-dr-allen-chen-as-vice-president-of-medical-affairs-and-clinical-development-oncology-6</guid>
<pubDate>Thu, 02 Apr 2026 04:00:00 GMT</pubDate>
<description>Renowned physician executive and clinician-scientist joins BillionToOne to advance oncology medical strategyMENLO PARK, Calif., April 2, 2026 /PRNewswire/ --</description>
</item>
<item>
<title>BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-reports-fourth-quarter-and-full-year-2025-results-and-raises-2026-revenue-guidance-124</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-reports-fourth-quarter-and-full-year-2025-results-and-raises-2026-revenue-guidance-124</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to</description>
</item>
<item>
<title>BillionToOne to Report Fourth Quarter and Full Year 2025 Financial Results on March 4, 2026</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-report-fourth-quarter-full-130500802</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-report-fourth-quarter-full-130500802</guid>
<pubDate>Tue, 17 Feb 2026 13:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for fourth quarter and full year ended December 31, 2025 after the market close on Wednesday, March 4, 2026. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:</description>
</item>
<item>
<title>BillionToOne Expands Northstar Platform with Launch of Two New Add-On Liquid Biopsy Applications for Northstar Select®</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-expands-northstar-platform-launch-140000315</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-expands-northstar-platform-launch-140000315</guid>
<pubDate>Tue, 10 Feb 2026 14:00:00 GMT</pubDate>
<description>BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of Northstar PGx and Northstar Select CH. Northstar PGx and Northstar CH are add-on applications for Northstar Select, the most sensitive therapy selection liquid biopsy for advanced solid tumors, as demonstrated in a head-to-head clinical study, proven to uncover 50%+ more clinically actionable alterations.</description>
</item>
<item>
<title>BillionToOne Announces Dual Launch of UNITY Expanded Red Blood Cell and Platelet Fetal Antigen NIPTs, Extending Its Leadership In Setting the New Standard in Prenatal Care</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-dual-launch-unity-172900211</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-dual-launch-unity-172900211</guid>
<pubDate>Mon, 09 Feb 2026 17:29:00 GMT</pubDate>
<description>BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the launch of UNITY's expanded Red Blood Cell (RBC) Fetal Antigen NIPT and a first-and-only Platelet Fetal Antigen NIPT. Available exclusively through the UNITY Aneuploidy™ Screen, these offerings represent the first-and-only non-invasive prenatal tests in the U.S. designed to determine fetal antigen status across both</description>
</item>
<item>
<title>BillionToOne Announces Collaboration with Epic to Expand Prenatal and Oncology Testing Across Healthcare</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-collaboration-epic-expand-135800343</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-collaboration-epic-expand-135800343</guid>
<pubDate>Thu, 15 Jan 2026 13:58:00 GMT</pubDate>
<description>BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced a collaboration with Epic, the nation's most widely used comprehensive electronic health record (EHR). The agreement, signed in December 2025, will integrate BillionToOne's prenatal and oncology testing portfolio with Epic's Aura diagnostics suite.</description>
</item>
<item>
<title>BillionToOne Provides Guidance for 2026</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-provides-guidance-2026-130500851</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-provides-guidance-2026-130500851</guid>
<pubDate>Mon, 12 Jan 2026 13:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reiterated the full year 2025 guidance of $293 million to $299 million with positive GAAP operating income and initiated the full year 2026 guidance. Full Year 2026 Guidance Full year 2026 total revenue of $415 million to $430 million, representing growth of 40% to 45% compar</description>
</item>
<item>
<title>BillionToOne Announces Selection of Northstar Select® as the new liquid biopsy test for LC-SCRUM-TRY clinical study at National Cancer Center Hospital East</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-selection-northstar-select-140000257</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-selection-northstar-select-140000257</guid>
<pubDate>Tue, 06 Jan 2026 14:00:00 GMT</pubDate>
<description>BillionToOne, Inc. (Nasdaq: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the selection of Northstar Select® as the new liquid biopsy in LC-SCRUM-TRY- Japan, a nationwide, multi-center study to better elucidate the mechanisms of drug resistance and the characteristics of drug-resistant lung cancer. Launched by the National Cancer Center Hospital East (Kashiwa, Japan; "NCCHE") in 2020 with ov</description>
</item>
<item>
<title>BillionToOne to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-participate-44th-annual-j-130500317</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-participate-44th-annual-j-130500317</guid>
<pubDate>Tue, 23 Dec 2025 13:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Dec. 23, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the 44th Annual J.P. Morgan Healthcare Conference. Management will present from 9:45am to 10:25am Pacific Time on Monday, January 12th, 2026. A live and archived webcast will be available on the “Events & Presentations” pa</description>
</item>
<item>
<title>BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-appoints-anthony-pagano-board-210700515</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-appoints-anthony-pagano-board-210700515</guid>
<pubDate>Tue, 09 Dec 2025 21:07:00 GMT</pubDate>
<description>BillionToOne Appoints Anthony Pagano to Board of Directors as Audit Committee Chair</description>
</item>
<item>
<title>BillionToOne Reports Third Quarter 2025 Results</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-reports-third-quarter-2025-210500646</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-reports-third-quarter-2025-210500646</guid>
<pubDate>Tue, 09 Dec 2025 21:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Dec. 09, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today reported its financial results for the third quarter ended September 30, 2025 and initiated guidance for the remainder of 2025. Recent Financial Highlights: Total revenue of $83.5 million in the third quarter of 2025, compared to $38.4 million in the third quarter of 2024, an</description>
</item>
<item>
<title>BillionToOne to Report Third Quarter 2025 Financial Results on December 9, 2025</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-report-third-quarter-2025-130500550</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-report-third-quarter-2025-130500550</guid>
<pubDate>Tue, 02 Dec 2025 13:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that the Company plans to release its financial results for third quarter ended September 30, 2025 after the market close on Tuesday, December 9, 2025. BillionToOne will host a conference call to discuss its financial results at 1:30pm Pacific Time / 4:30pm Eastern Time the same da</description>
</item>
<item>
<title>BillionToOne Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-closing-upsized-initial-210500485</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-closing-upsized-initial-210500485</guid>
<pubDate>Fri, 07 Nov 2025 21:05:00 GMT</pubDate>
<description>MENLO PARK, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the closing of its upsized initial public offering of 5,233,765 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase an additional 682,665 shares of Class A common stock at a public offering price of $60.00 per share, less underwriting di</description>
</item>
<item>
<title>BillionToOne Announces Pricing of Upsized Initial Public Offering</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-pricing-upsized-initial-025300842</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-pricing-upsized-initial-025300842</guid>
<pubDate>Thu, 06 Nov 2025 02:53:00 GMT</pubDate>
<description>MENLO PARK, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (Nasdaq: BLLN), a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced the pricing of its upsized initial public offering of 4,551,100 shares of its Class A common stock, at a public offering price of $60.00 per share. In addition, BillionToOne has granted the underwriters a 30-day option to purchase up to an additional 682,665 shares of its Class A c</description>
</item>
<item>
<title>BillionToOne Announces Launch of Initial Public Offering Roadshow</title>
<link>https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-launch-initial-public-100000965</link>
<guid isPermaLink="true">https://6ix.com/company/billiontoone-inc-class-a-common-stock/news/billiontoone-announces-launch-initial-public-100000965</guid>
<pubDate>Wed, 29 Oct 2025 10:00:00 GMT</pubDate>
<description>MENLO PARK, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- BillionToOne, Inc., a molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that it has launched the roadshow for its proposed initial public offering of 3,846,000 shares of its Class A common stock. In addition, BillionToOne intends to grant the underwriters a 30-day option to purchase up to an additional 576,900 shares of its Class A common stock at the initial public</description>
</item>
</channel>
</rss>